Most Recent Articles by Susan Jenks
While liquid biopsies could prove successful in monitoring treatments, these tests might also find early-stage cancers that, left alone, would never progress.
Whether cryosurgery or cryoablation will prove a viable alternative to lumpectomy — the standard of care for women with early breast cancer — remains uncertain.
A pooled analysis of 3 combination drug regimens used to treat refractory/relapsed multiple myeloma reaffirms their safety, but does little to distinguish which approach works best.
For Merkel-cell cancers—the deadliest and rarest type—there are no approved drugs once surgery and radiation fail.
Physicians and cancer organizations suggest more research is needed before the Epi proColon blood test becomes a standard screening approach.
More Articles by Susan Jenks
FDA Approves Second Biosimilar Since Releasing Labeling Guidance, Despite Patent Protection, Safety ConcernsApr 28,2016
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Ultrasonography May Detect Thyroid Cancer Growth Arrest, Negating Need for Treatment
- Do Additional Chromosomal Abnormalities Noted at CML Diagnosis Affect Response and Survival?
- Does Education Level Predict PSA Screening and Prostate Cancer Survival?
- Pembrolizumab May Benefit Selected Patients With Incurable Metastatic Breast Cancer
- Unrelated HSCT, UCBT May Yield Similar Survival Outcomes in Acute Leukemia
- Adjuvant Gefitinib Improves Disease-free Survival Among Patients With NSCLC
- Phase 1 Study of Binimetinib Plus Pexidartinib for GIST
- Phase 2 Study of Nivolumab vs Nivolumab Plus Ipilimumab for GIST
- Pesticides and Cancer
- Goserelin Mitigates Risk of Ovarian Failure, Improves Breast Cancer Survival Rate